TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02547324

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Slump sitting
Description: Patients are asked to sit slumped on the chair as much as possible without leaning forwards, and place you hands below your thighs.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Forward bending
Description: Patients are asked to stand with both feet placed together, hands behind their heads, and bend forward in this position as much as possible without falling
Study: NCT01745068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated program
Description: Each participant's primary care physician will receive written information containing a presumed osteoporosis diagnosis, investigations to be performed, correct interpretation of any bone densitometry results in the context of a fragility fracture, and treatment options. The study coordinator will be responsible for orienting the participant to an appropriate local fall prevention program.
Study: NCT00785876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LRAR Implementation
Description: Pre-LRAR - no changes in the usual procedures for the first 26 weeks except for flagging of all paediatric charts with ankle injuries, ED documentation which will not refer to the LRAR and phone follow up.~Post-LRAR: At 27 weeks, in addition to the aforementioned ED collection sheet and phone follow up, the implementation strategy for the LRAR rule and related management will be introduced at the intervention hospitals.
Study: NCT01321437

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib will be administered 5 mg orally twice each day (BID) continuously. Dose adjustments will be based on adverse events.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01679431

Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler-echocardiography

Intervention type: RADIATION
Intervention: Computed tomography

Intervention type: OTHER
Intervention: Magnetic resonance imaging

Intervention type: BIOLOGICAL
Intervention: Fasting blood sample
Study: NCT01023776

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: A/California/07/09 live monovalent H1N1 vaccine
Description: 0.1mL per nares intranasally, second identical dose given 28 days after first vaccine
Study: NCT02937363

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid
Description: A trial of exercise before and after 4 weeks of alpha-lipoic acid supplementation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A trial of exercise before and after 4 weeks of placebo administration.
Study: NCT04374188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: drug adminstration to ameliorate sepsis incidence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: levofloxacin pill
Study: NCT01086228

Intervention type: DEVICE
Intervention: XIENCE V / PROMUS stent
Description: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.
Study: NCT02459886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB054
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB054
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB054
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB054
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB054
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB054
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB054
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion
Study: NCT00173888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin
Description: docetaxel 36mg/m2 IF 30 mins on day 1,8,15 cisplatin 75mg/m2 IF 2 hrs on day 15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine, Cisplatin
Description: gemcitabine 1000mg/m2 IF 30mins on D 1,8,15, cisplatin 75mg/m2 IF 2 hrs on day 15
Study: NCT04295551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir / ritonavir tablets combined with Xiyanping injection
Description: Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir / ritonavir tablets combined with Xiyanping injection
Description: Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir treatment
Description: Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization
Study: NCT03591185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FallSensing Clinical Tool
Description: FallSensing clinical tool will be applied to a group of community-dwelling adults aged 50 years or over, including a initial evaluation, 24 intervention sessions (2 or 3 sessions per week) and a final evaluation.~Inicial and final evaluation consists in six functional tests (Grip Strength, Timed Up and Go, 30 seconds Sit-to-Stand, Step test, 4 Stage Balance test modified and 10 meters Walking Speed) and a questionnaire concerning self-efficacy for exercise.
Study: NCT02687243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interactive Virtual Application
Description: Online application via tablet
Study: NCT02197234

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling - AZD9291
Description: Blood sampling to measure AZD9291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin (CYP substrate) 40mg taken once daily on Days 1 and 31 (Part A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291 tablet dosing
Description: AZD9291 80mg tablet taken from Days 3 to 32. (Part B) AZD9291 80mg tablet taken daily for 12 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling - simvastatin
Description: Blood sampling to measure simvastatin levels

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling - AZ5140 and AZ7550
Description: Blood samples to measure levels of AZ5140 and AZ7550
Study: NCT02459886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion
Study: NCT02512692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: On days 1 and 8 of each cycle (21 days) Gemcitabine will be administered. Treatment may last up to 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: On days 1 and 8 of each cycle (21 days) Cisplatin will be administered. Treatment may last up to 8 cycles
Study: NCT03491215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: All enrolled pediatric participants received ruxolitinib as a 5 mg tablet (adult and adolescent formulation) or an oral pediatric formulation (administered as oral solution or capsule dispersed in liquid).
Study: NCT03835819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is an immunotherapy that activates a patient's own immune system to recognize and kill tumor cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGN853
Description: Mirvetuximab soravtansine is an antibody-drug conjugate.
Study: NCT04638296

Intervention type: OTHER
Intervention: Interviews
Description: The investigators designed 3 versions of the semi structured interview guide for each of the surgeons/anesthesiologists (Appendix A.1), residents (Appendix A.2) and nurses (Appendix A. 3). All versions were subdivided into 3 general categories: 1) participant demographics such as participant's age, years of experience, specialty, years of employment at the institution 2) participant's perceptions of noise in the OR, what they considered as sources of noise, the loudness level, whether they thought this impacted their concentration, performance, communication, whether this was distracting or helpful in different stages of the operation, and 3) perceptions on music.

Intervention type: OTHER
Intervention: Interviews
Description: The investigators designed 3 versions of the semi structured interview guide for each of the surgeons/anesthesiologists (Appendix A.1), residents (Appendix A.2) and nurses (Appendix A. 3). All versions were subdivided into 3 general categories: 1) participant demographics such as participant's age, years of experience, specialty, years of employment at the institution 2) participant's perceptions of noise in the OR, what they considered as sources of noise, the loudness level, whether they thought this impacted their concentration, performance, communication, whether this was distracting or helpful in different stages of the operation, and 3) perceptions on music.
Study: NCT02722486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation/Balance Belt
Description: With this device, a subject stands on a force platform on the ground, which measures his/her center of pressure. Additionally, there is laptop displaying the video-based exercise programs and a camera that senses the subject's linear sway, roll, and pitch. Information about the subject's position is transmitted via Bluetooth technology to a non-invasive vibrotactile belt which fits comfortably around the subject's waist, over his/her clothing. Using the Sensory Kinetics software, the subject will play a series of games projected on the laptop screen, which prompt him/her to sway in various directions while keeping both feet planted on the force platform.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Vestibular Rehabilitation
Description: This is the standard three-month vestibular rehabilitation therapy that patients are routinely referred to at Boston Children's Hospital.
Study: NCT03098355

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR19/22 T cells
Description: CD19/CD22-targeted 4th Generation CAR-T Cell (4SCAR19/22)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 of 250,000iu/m\^2 every other day for 2 weeks and then rest for 2 weeks for up to 6 months.
Study: NCT01969643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ladiratuzumab vedotin
Description: LV will be given into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ladiratuzumab vedotin
Description: LV will be given into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ladiratuzumab vedotin
Description: LV will be given into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be given by IV every 3 weeks at a dose of 6 mg/kg (the first dose will be 8 mg/kg)
Study: NCT03644680

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nasal Provocation with Birch Extract
Description: Nasal spray containing birch extract from Allergopharma

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Provocation with NaCl 0.9%
Description: Nasal spray containing sterile sodium chloride 0.9%
Study: NCT04860427

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: trapezoidal condylar plate
Description: trapezoidal condylar plate open reduction and fixation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: two miniplates
Description: two miniplates open reduction and fixation
Study: NCT06193525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib is administered daily as single agent, 1 mg orally until unacceptable toxicity or progression of disease.
Study: NCT02600351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT01961245

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nocturnal non-invasive ventilation
Description: patients will undergo a non-invasive ventilation during the night
Study: NCT01843309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01565759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: The dose has been selected in order to achieve a therapeutic range of 0.6 - 0.8 mmol/L.~Dose titration Day 1: 1 capsule of 300 mg at bedtime Days 2 to 7: 1 capsule of 600 mg at bedtime Day 8: lithium serum levels will be tested and the dose will be adjusted proportionally to a target range of 0.6 - 0.8 mmol/L by increments of 150 mg or 300 mg.
Study: NCT03162211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback Report
Description: There are two types of feedback forms: 1. Patient feedback forms and 2. Clinician feedback forms. Feedback form content has been developed in consultation with a board of clinicians, service providers, and patients living with depression. Feedback forms will be comprehensive and condensed to a one page report including graphical presentations of symptom course and text. Clinician feedback forms will include content on depression severity over time and recommendations for individualized treatment. Patient feedback forms will also incorporate depression severity over time as well as summary information on achievement towards personalized treatment goals.
Study: NCT02599831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical pudendal nerve stimulation
Description: Four sacrococcygeal points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the root of the penis (perineum) or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the root of the penis (perineum). After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFM training
Description: A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transanal ES
Description: A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
Study: NCT01847014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan tablet, dose of 10 mg, once daily.
Study: NCT01813110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 g prescription omega-3 concentrate
Description: 4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: olive oil
Study: NCT04087213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemoCare™ Hemodialysis System
Description: The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
Study: NCT02671409

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neural Mobilization (exercise)
Description: Initially patients will be informed about the procedures. After the guidelines, the hip and knee are palpated to start the joint angles. Then, the knee joint is positioned in extension and remained so throughout the treatment. In addition, the hip joint is bent until the moment that will be perceived a minimum strength of the muscles of the posterior region of thigh and leg (discarding muscle stretching). Neural mobilization is started at the time when the ankle joint will be manipulated in dorsiflexion at a frequency of approximately 20 oscillations per minute, with a pause of 25 seconds of rest. In the last two minutes of therapy, we will include cervical flexion, in order to intend the neuraxis, keeping artuculares amplitudes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Mobilization (exercise)
Description: Initially patients will be informed about the procedures. After the guidelines, the hip and knee are palpated to start the joint angles. Then, the knee joint is positioned in extension and remained so throughout the treatment. In addition, the hip joint is bent until the moment that will be perceived a minimum strength of the muscles of the posterior region of thigh and leg (discarding muscle stretching). Neural mobilization is started at the time when the ankle joint will be manipulated in dorsiflexion at a frequency of approximately 20 oscillations per minute, with a pause of 25 seconds of rest. In the last two minutes of therapy, we will include cervical flexion, in order to intend the neuraxis, keeping artuculares amplitudes.
Study: NCT02380027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: This will be a multi-parametric MRI of the prostate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI-targeted biopsy
Description: This will be a biopsy targeted to suspicious areas on the MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TRUS-biopsy
Description: This will be a standard 12 core trans-rectal prostate biopsy
Study: NCT02413372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02081131

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: pancreatic head resection by open method

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic surgery
Description: laparoscopic pancreatoduodenectomy
Study: NCT03824418

Intervention type: PROCEDURE
Intervention: Surveillance colonoscopy with chromoendoscopy
Description: Surveillance colonoscopy with chromoendoscopy

Intervention type: PROCEDURE
Intervention: Surveillance colonoscopy with chromoendoscopy
Description: Surveillance colonoscopy with chromoendoscopy
Study: NCT04040270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live drama+DVD+Worksheets
Description: Interactive live drama was proposed to enhance memories of the audience of health promotion programmes.~The interactive live drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD+Worksheets
Description: The DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents.
Study: NCT04575454

Intervention type: OTHER
Group type: OTHER
Intervention: Multimodal evaluation of brain function : PET-MRI, electrophysiology, eye-tracking
Description: After 2 days of sedation withdrawal, each data should be collected within 3 days for organisation purposes :~1. After installation and movement management with standardized routine care protocol: 18Fluoro-Desoxy-Glucose's infusion for PET~2. Starting PET continuous acquisition~3. Morphological MRI sequences~4. MRI in Resting state N°1~5. MRI DTI acquisition~6. IRM in 2D-Arterial Spin Labelling~7. IRM in Resting state 2~8. End of PET continuous acquisition The day before or the day after PET-MR: standard 20 min EEG, somaesthetic evoked potentials, auditory evoked potentials, mismatch negativity, P300 oddball paradigm, local-global paradigm, P300 after music stimulation, EEG resting state for 10 min, CRS-R repeated before each examination (and at least 5 times for chronic patients), eye-tracking study of the environmental exploration.
Study: NCT01722773

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipap (Respironics, Inc)
Description: Bipap every night pressure at 15/5 with heated humidifier